Mesothelin (MSLN) has become a new immune target, employing regional routes of delivery, introducing novel modifications leading to enhanced tumor infiltration and persistence, and improved safety profiles and combining anti-MSLN CAR-T cells with standard therapies, which could render them more efficacious in the treatment of solid malignancies [13,14]. The gene discussed is MSLN; the disease is neoplasm.